Anesthesia & Analgesia, Vol 80, 296-302, Copyright © 1995 by International Anesthesia Research Society
Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain
KP Leow, T Cramond and MT Smith
Department of Surgery, University of Queensland, Royal Brisbane Hospital, Australia.
The single-dose pharmacokinetics and pharmacodynamics of oxycodone
administered by the intravenous and rectal routes were determined in 12
adult cancer patients with moderate to severe cancer pain (visual analog
scale [VAS] score, approximately 5). Oxycodone was administered by the
intravenous and rectal routes with open drug administration and a
cross-over design. After single-dose intravenous administration (7.9 +/-
1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/-
1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the
mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg
(+/- 1.1). After rectal oxycodone (30 mg), the mean (+/- SD) absorption lag
time was 0.52 h (+/- 0.29) and the mean (+/- SD) absolute bioavailability
was 61.6% (+/- 30.2%). Intravenous oxycodone was associated with a rapid
onset of pain relief (5-8 min) in contrast to the 0.5- to 1.0-h delay
observed after rectal administration. However, rectal oxycodone provided
analgesia of much longer duration (approximately 8-12 h) than did
intravenous oxycodone (approximately 4 h). There were no significant
differences (P > 0.05) in the incidence and severity of side effects
between intravenous and rectal oxycodone. The marked interindividual
variation observed in the pharmacokinetics and pharmacodynamics of
oxycodone in this study emphasizes the need for individualized dosing
regimens.